A small Singapore biotech is placing a substantial bet on an idea that's equal parts promising and unproven: that the right kind of heart failure isn't really about the heart at all.
Brano Therapeutics, spun out from Duke-NUS Medical School, closed a $6.8 million seed round in May 2026 to pursue small-molecule therapies for heart failure with preserved ejection fraction—a condition cardiologists sometimes call the most vexing problem in modern heart medicine. The funding came from a quartet of investors that reads like a who's-who of Singapore's deep-tech ecosystem: Trinity Innovation Bioventure Singapore and SEEDS Capital co-led, with SGInnovate and Duke-NUS's LIVE Ventures fund filling out the syndicate.
LIVE Ventures committed $380,000, equivalent to S$500,000, according to the company. For context, that's close to the fund's stated maximum check size for individual spinouts—a signal, perhaps, of institutional confidence in the science, or at least in the commercial potential of a market measured in tens of billions.
The Half of Heart Failure Nobody Can Treat
Studies suggest HFpEF accounts for nearly 50% of heart failure cases. In the United States alone, the condition affects approximately 3 million people, according to company data, part of a broader heart failure epidemic that the Heart Failure Society of America pegs at 6.7 million adults today, climbing toward 8.7 million by decade's end.
What makes HFpEF particularly maddening is its paradox. Unlike traditional heart failure, where weakened muscles struggle to pump blood, HFpEF patients retain normal pumping strength. The ejection fraction—a standard measure of cardiac function—looks fine. Yet they experience all the hallmarks of heart failure: breathlessness, fatigue, fluid retention. It's heart failure hiding in plain sight.
The condition clusters with metabolic disorders: hypertension, diabetes, obesity. Standard heart failure medications, designed for weakened hearts, largely fail in this population. The treatment cupboard, in other words, is nearly bare.
Betting on Broken Metabolism
Brano's scientific thesis centers on metabolic dysfunction in cardiac tissue. The company licensed its core technology from Duke-NUS, where scientific founder Yibin Wang—who directs the institution's cardiovascular and metabolic disorders research program—identified what the team describes as a distinct metabolic signature in HFpEF patients. The defect, they believe, lies in how heart cells process nutrients.
In preclinical animal work, correcting this metabolic breakdown appeared to slow disease progression. Brano's lead program uses small molecules designed to boost metabolic capacity in failing hearts—essentially, fixing the cellular power plant.
The metabolic hypothesis has been gaining traction industry-wide. Johns Hopkins researchers published findings earlier this year linking severe obesity to impaired heart muscle contraction in HFpEF patients, with data suggesting weight loss can reverse the damage. It's the kind of connection Brano is banking on, though translating animal data and observational studies into effective human therapies remains, as always in biotech, the harder part.
Singapore's Coordinated Capital
The investor lineup reflects Singapore's deliberate strategy for commercializing academic research. TIBS brings biomedical expertise and regional connections. SEEDS Capital operates as a co-investment platform backed by Enterprise Singapore and the Economic Development Board—essentially, government money deployed alongside private capital. SGInnovate specializes in shepherding deep-tech research toward market viability.
LIVE Ventures, launched in 2024 with $20 million under management, exists specifically to fund Duke-NUS spinouts, offering up to half a million Singapore dollars per project. The fund recently showcased Brano as an example of successful academic translation—perhaps premature, given the company hasn't yet dosed its first human patient, but illustrative of the ecosystem's ambitions.
The Long Road Ahead
The seed capital will fund Brano's push toward clinical trials, with the company aiming to reach that milestone by 2029. Langdon Wu, a biomedical strategist with industry experience, leads as CEO. The scientific team includes Chen Gao, focused on RNA metabolism in cardiac disease, alongside advisors from Johns Hopkins and the University of Glasgow with HFpEF trial expertise.
Founded in 2025, Brano operates out of Singapore Science Park with a staff numbering somewhere between two and ten, according to LinkedIn. The global heart failure therapeutics market sits around $29 billion to $32 billion, with forecasts projecting growth past $60 billion by the early 2030s as aging populations drive incidence upward.
Those are attractive numbers. Whether Brano's metabolic approach can deliver where conventional therapies have stumbled—well, that's the $6.8 million question. The seed funding buys the company runway to test a hypothesis: that fixing how heart cells generate energy might address a condition affecting tens of millions worldwide.
It's a big if. But in a field where treatment options remain frustratingly limited, even a long shot starts to look worth taking.
